Sign in

    Basma Radwan

    Vice President and Equity Research Analyst at Leerink Partners

    Basma Radwan, Ph.D., is a Vice President and Equity Research Analyst at Leerink Partners, specializing in the coverage of rare disease and diversified biopharmaceutical companies. She covers firms including Zymeworks Inc., Bicycle Therapeutics plc, Genmab A/S, Xencor, Inc., Zai Lab Ltd, ACADIA Pharmaceuticals Inc., AC Immune SA, and Aldeyra Therapeutics, among others, with her coverage universe noted for strong and differentiated recommendations. Her performance track record includes high ratings for accurate earnings projections, and her recent sector universe has consistently delivered competitive returns in healthcare investment strategies. Radwan began her equity research career after earning her doctorate, is registered with FINRA (CRD#: 7509486), and holds applicable securities licenses, reflecting her deep industry expertise and regulatory credentials.

    Basma Radwan's questions to Xenon Pharmaceuticals (XENE) leadership

    Basma Radwan's questions to Xenon Pharmaceuticals (XENE) leadership • Q2 2025

    Question

    Basma Radwan from Leerink Partners inquired about the clinical differences between Type I and Type II bipolar depression, whether Ezetucalner is expected to have differential efficacy, and if mania is being assessed as an endpoint in the trial.

    Answer

    Chief Medical Officer Christopher Kenney explained that Type I involves manic episodes while Type II involves hypomania, and the trial includes both populations with stratification to ensure balance. He stated that while they expect efficacy in both, it is unknown. Mania is being monitored as a safety outcome to ensure the drug does not exacerbate the condition, rather than as an efficacy endpoint.

    Ask Fintool Equity Research AI